Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group
Jefferies Financial Group upgraded shares of Relmada Therapeutics (NASDAQ:RLMD – Free Report) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning, MarketBeat Ratings reports. Jefferies Financial Group currently has $13.00 price target on the stock, up from their previous price target of $3.50. Separately, The Goldman […]
21 Sep 07:09 · The Markets Daily